For Immediate Release

Chicago, IL – December 01, 2014– Zacks Equity Research highlights American Airlines (AAL-Free Report) as the Bull of the Day and Stone Energy (SGY-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on GlaxoSmithKline (GSK-Free Report), Merck (MRK-Free Report) and NewLink Genetics Corporation (NLNK-Free Report).

Here is a synopsis of all five stocks:

Bull of the Day:

Despite winter storm worries, the airline sector has been flying pretty high as of late and for good reason too. The segment is experiencing one of its most profitable and in-demand stretches in years, and many believe the run could continue into 2015 too.

After all, with the rash of mergers over the past few years, airline competition is relatively low giving many airlines pricing power in a number of key routes. Strong consumer demand hasn’t hurt matters either as a more willing-to-spend traveler seems ready to pony up for higher fares, while a more certain job situation is acting as a catalyst for more vacations as well.

And while Ebola worries might have temporarily derailed the sector, the space has fought back quickly and is riding high thanks to one of their highest input costs; oil. Crude oil prices—and thus jet fuel prices—have come down significantly in recent weeks, boosting profits for airlines across the sector, and setting up the space for a stellar start to the New Year.

For these reasons, it is easy to see why the airline industry is in the top 20% of all industries that we cover. And while any number of stocks in this space could be solid in this great environment, a look towards American Airlines (AAL-Free Report) in particular could be an exceptional idea right now.

American Airlines is by some measures the largest airline in the world, serving customers across the globe with more than 6,700 daily flights in 56 nations. The company is the result of a merger between AMR (American Airlines' parent group) and US Airways, continuing the recent trend of consolidation in the industry.

Speaking of trends, American Airlines has, just like its peers, been able to soar in recent times and put up solid profitability numbers as well. Yet even with an 80% surge YTD, there is plenty of reason to hope for more gains heading into 2015 too. This is especially true when investors look to recent earnings estimate revisions for AAL, which definitely suggest more strength ahead for the company.

Bear of the Day:

Crude oil prices have been on an incredible downward slide over the past few months. Prices are now in the range of multi-year lows and there is little near term hope for an upswing. After all, there are some significant forces at play in the oil market, making it difficult to see a move higher in 2015.

The stronger dollar has definitely had an impact, as oil is traded in dollars around the globe. So, when translated into foreign currencies, international producers need less to receive the same domestic value for each oil barrel sold.

Speaking of foreign markets, demand has also been pretty weak in a number of these segments, an area that was an important source of demand growth in the near term. And though many nations are resorting to more stimulus in an attempt to boost economies (and thus oil demand), many have had little impact so far, keeping a lid on oil prices in the process.

If that wasn’t enough, we have a huge oversupply situation back in the U.S. thanks to improving fracking technologies. This is further putting pressure on oil prices, making for a terrible situation for those long in crude oil in the near term.

With this backdrop, investors shouldn’t be too surprised to note that energy stocks have been at the bottom of the industry list, and have been seeing slumping earnings estimates as of late. One such stock that is a great example of this trend is undoubtedly Stone Energy (SGY-Free Report), a company that is in the exploration and production segment of the energy industry.

Additional content:

Glaxo’s Ebola Candidate Well-Tolerated in Early Study

Initial results from a small phase I study revealed that GlaxoSmithKline’s (GSK-Free Report) Ebola vaccine candidate was well-tolerated in 20 adult volunteers in the U.S. The results were published in the New England Journal of Medicine.

Results further showed that the candidate produced an immunological response in all of the volunteers who received the vaccine. Glaxo is collaborating with the U.S. National Institutes of Health (:NIH) to develop this vaccine.

Glaxo intends to share results from additional phase I studies (running in the U.S., UK, Mali and Switzerland) on the Ebola candidate in the coming weeks. Results from a phase I study being conducted in Mali will be mostly awaited. The study is evaluating the safety and immune response of the candidate in patients from West Africa, the region most affected in the latest outbreak of this deadly virus.

Depending on the positive outcome from these phase I studies, Glaxo plans to initiate phase III studies on the candidate early next year. The company’s phase III studies will involve the vaccination of thousands of health care workers from Sierra Leone and Liberia. The company also has plans to conduct additional safety studies in West African countries.

Our Take

Glaxo’s Ebola candidate is one of the promising in clinical trials right now. We expect investors focus to stay on the candidate’s future updates. Other big players are also in the race for the successful development of an Ebola vaccine.

Earlier in the week we have seen Merck (MRK-Free Report) buying rights to an Ebola vaccine candidate, rVSV-EBOV, from NewLink Genetics Corporation (NLNK-Free Report) for around $50 million (read more: Merck Buys Rights to Ebola Vaccine Candidate from NewLink).

The NIH intends to start a large randomized, controlled phase III study in early 2015 on Glaxo’s Ebola vaccine candidate and rVSV-EBOV.

We have seen investors keenly following Ebola related news over the last several months.

This year has seen the worst ever outbreak of the deadly virus with no approved treatment so far.

Glaxo is currently a Zacks Rank #5 (Strong Sell) stock.

Get today’s Zacks #1 Stock of the Day with your free subscription to Profit from the Pros newsletter:

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Click here to subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on AAL - FREE
Get the full Report on SGY - FREE
Get the full Report on GSK - FREE
Get the full Report on MRK - FREE
Get the full Report on NLNK - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on AAL

Read the analyst report on SGY

Read the analyst report on GSK

Read the analyst report on MRK

Read the analyst report on NLNK


Zacks Investment Research